RELIEF THERAPEUTICS Holding SA announces an agreement with the University of Freiburg for the clinical development of Aviptadil in Sarcoidosis

06 November 2017

RELIEF THERAPEUTICS Holding SA (“Relief”, “the Company”) is pleased to announce that the non-commercial, development-focused agreement that it has established with the Department of Pneumology of the University Medical Centre of the University of Freiburg, Germany (“Pneumology Clinic”), has led to the attribution of a significant grant from the DFG to the Pneumology Clinic to support the clinical development of Aviptadil in Sarcoidosis. DFG awards grants through a highly competitive application and review process to support the clinical development of promising compounds in Germany.

This current agreement follows a precedent collaboration between Relief and the Department of Pneumology that led to the completion of an open-label Phase II study that unravelled the clinical potential of inhaled Aviptadil to treat pulmonary sarcoidosis patients (AVISARCO I). The DFG grant attributed now to the Department of Pneumology will allow the further exploration of the therapeutic benefit of Aviptadil. This will be carried out following a double blind, randomized, placebo-controlled, multi-centre protocol including patients at different German clinical centres.

Professor Dr. Joachim Müller-Quernheim, Director of the Department of Pneumology of the University Medial Centre of the University of Freiburg says: “Aviptadil has the potential to become the first drug to be approved for the treatment of the rare disease sarcoidosis which leads to pulmonary function defects and reduces patients’ life span„

Dr. Raghuram Selvaraju, chairman of the Board of Directors of Relief states: “We are extremely pleased that the German Research Foundation, self-administrated by German scientists, recognizes the potential of aviptadil for the treatment of pulmonary sarcoidosis and entrusts Prof. Dr. Joachim Müller-Quernheim from the Department of Pneumology of the Albert-Ludwigs-University Freiburg to lead this investigator initiated trial. This grant constitutes a true opportunity to assess the ability of aviptadil to treat pulmonary sarcoidosis and to subsequently provide a potential new treatment for this orphan indication.”

About the Pulmonology Clinic of the Albert-Ludwigs-University Freiburg:

The department of pneumology provides high-level scientific expertise, interdisciplinary care including lung transplantation and specialized diagnostics for patients with any pulmonary disease. Interstitial lung diseases, including but not limited to sarcoidosis, idiopathic pulmonary fibrosis, chronic beryllium disease, non-specific interstitial pneumonia, and lymphangioleiomyomatosis are in the focus. More than 900 patients with all types of interstitial lung diseases are diagnosed and treated per year. The department of pneumology consists of 5 modules. Patient care is organised in the out-patient clinic (i) and the pneumology ward (ii). The bronchoscopy module (iii) offers advanced bronchoscopy services including endobronchial ultrasound guided biopsies and cryobiopsies. The pulmonary function laboratory (iv) performs all tests required for clinical investigation of pulmonary physiology. The research laboratory (v) performs clinical analyses of bronchoalveolar lavage and delivers specialized diagnostics such as lymphocyte proliferation tests. The primary task of this laboratory is basic science in the area of interstitial lung diseases and the corresponding clinical trials.


RELIEF THERAPEUTICS Holding SA is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (to enter Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (to enter Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, and has been the subject of multiple clinical trials. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Geneva, Switzerland.

For further information, please visit the Relief website at  or contact investor relations.

RELIEF THERAPEUTICS Holding SA Investor Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.


This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.